Richter-Helm BioLogics GmbH & Co. KG (Hamburg, Germany) and Athera Biotechnologies AB (Stockholm, Sweden) have signed an agreement for the development and manufacturing of Annexin A5, Athera?s novel product for prevention of plaque rupture and athero-thrombosis.
Richter-Helm BioLogics GmbH & Co. KG (Hamburg, Germany) and Athera Biotechnologies AB (Stockholm, Sweden) have signed an agreement for the development and manufacturing of Annexin A5, Athera’s novel product for prevention of plaque rupture and athero-thrombosis.
Annexin A5 is produced using Richter-Helm’s proprietary E. coli–based expression system. Richter-Helm will initiate strain and process development of the new process to a 1,000 L production scale.
The recombinant protein Annexin A5 is intended for the treatment of patients with acute coronary syndrome and who are at imminent risk for myocardial Infarction.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.